Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF
Novel genomic test distinguishes IPF from other lung-scarring diseases without the need for surgery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Veracyte, Inc . announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company’s Envisia
View HTML
Toggle Summary Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 18 th Annual Needham Healthcare Conference in New York
View HTML
Toggle Summary Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
Findings Presented at ENDO 2019 Conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 25, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with
View HTML
Toggle Summary Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition
Support Reinforces Company’s Commitment to Tackling This Deadly Disease SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team
View HTML
Toggle Summary Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine
View HTML
Toggle Summary Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier
Genomic Test is the First to Be Granted Medicare Coverage for Improved Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 4, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it has received a final Medicare local coverage determination
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
2018 Revenue Grew 28% to $92 million Three Commercial Products and Biopharma Collaborations to Drive Growth in 2019 Company to Host Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 25, 2019-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 20, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that members of its management team will be participating in two upcoming investor conferences. Executives from the company will be meeting with investors at the BTIG MedTech, Life Science &
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 28, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019 . Company management will host a conference call
View HTML